Brain Cancer Clinical Trials in Los Angeles

Showing 61-79 of 79 trials

A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma

NCT02049489

This study will evaluate a type of immunotherapy in which the patient's immune system will be stimulated to kill tumor cells. ICT-121 dendritic cell (DC)vaccine is made from patient's white blood cells. This vaccine will be tested in patients with recurrent glioblastoma to assess safety, tolerability and clinical response. Patient's white blood cells (WBC) will be collected from blood and cultured to yield autologous DC. The DC will be mixed with purified peptides from the CD133 antigen. The DC vaccine will be given back to the patient over several months. The goal is to stimulate the patient's immune system to CD133 to kill the patient's glioblastoma tumor cells.

Glioblastoma Multiforme

Precision Life Sciences Group20 participantsStarted Dec 2013

Birmingham, Alabama, United States • La Jolla, California, United States • Los Angeles, California, United States +3 more locations

COMPLETEDPHASE1/PHASE2< 1 mile

Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

NCT00045110

Phase I/II trial to study the effectiveness of erlotinib in treating patients who have recurrent malignant glioma or recurrent or progressive meningioma. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.

Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell Glioblastoma+6 more

National Cancer Institute (NCI)136 participantsStarted Aug 2002

Los Angeles, California, United States • San Francisco, California, United States • Bethesda, Maryland, United States +4 more locations

A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma

Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

Brain Cancer Trials in Other Cities

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma

Expanded Access to ANG1005 for Individual Patients

A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

Other Conditions in Los Angeles